Febrile neutropenia: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
| style="vertical-align: middle; padding: 5px;" align=center | [[Febrile neutropenia resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | | style="vertical-align: middle; padding: 5px;" align=center | [[Febrile neutropenia resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | ||
|} | |} | ||
{{For|patient information|{{PAGENAME}} (patient information)}} | |||
{{Febrile neutropenia}} | {{Febrile neutropenia}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 17:59, 4 March 2015
|
Resident Survival Guide |
|
Febrile Neutropenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Febrile neutropenia On the Web |
|
American Roentgen Ray Society Images of Febrile neutropenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: F and N; fever and neutropenia; FN; hot and low; hot leuk; neutropenic fever; neutropenic fever syndrome; neutropenic sepsis
Overview
Historical Perspective
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | Initial Assessment | History and Symptoms | Physical Examination | Laboratory Findings | CT | Other Diagnostic Studies
Treatment
Medical Therapy | Primary Prevention
Guideline Sources
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America[1]
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline[2]
- Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation: American Society of Clinical Oncology Endorsement[3]
- Prevention and Treatment of Cancer-Related Infections: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology[4]
- Management of Febrile Neutropenia: European Society for Medical Oncology Clinical Recommendations[5]
References
- ↑ Freifeld, Alison G. (2011-02-15). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (4): 427–431. doi:10.1093/cid/ciq147. ISSN 1537-6591. PMID 21205990. Unknown parameter
|coauthors=ignored (help) - ↑ Flowers, Christopher R. (2013-02-20). "Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 31 (6): 794–810. doi:10.1200/JCO.2012.45.8661. ISSN 1527-7755. PMID 23319691. Unknown parameter
|coauthors=ignored (help) - ↑ Lehrnbecher, Thomas (2012-12-10). "Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 30 (35): 4427–4438. doi:10.1200/JCO.2012.42.7161. ISSN 1527-7755. PMID 22987086. Unknown parameter
|coauthors=ignored (help) - ↑ "Prevention and Treatment of Cancer-Related Infections" (PDF).
- ↑ Marti, F. Marti (2009-05). "Management of febrile neutropenia: ESMO clinical recommendations". Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 20 Suppl 4: 166–169. doi:10.1093/annonc/mdp163. ISSN 1569-8041. PMID 19454445. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help)